These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29595317)

  • 21. Using American Type Culture Collection Cell Lines to Evaluate Interlaboratory Variables for Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Immunostaining.
    Witt BL; Zhou W; Ambaye AB; Bellizzi A; Booth CN; Sundling K; Nguyen L; Russell DK; Schinstine M; Staats PN; Thomsen J; Troxell M; Souers RJ; Dvorak J; Lin X; Kurtycz DFI
    Arch Pathol Lab Med; 2023 Feb; 147(2):143-148. PubMed ID: 35639575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
    Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
    Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
    Mouttet D; Laé M; Caly M; Gentien D; Carpentier S; Peyro-Saint-Paul H; Vincent-Salomon A; Rouzier R; Sigal-Zafrani B; Sastre-Garau X; Reyal F
    PLoS One; 2016; 11(2):e0146474. PubMed ID: 26829108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
    Rhodes A; Jasani B; Balaton AJ; Miller KD
    J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
    J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.
    Griggs JJ; Hamilton AS; Schwartz KL; Zhao W; Abrahamse PH; Thomas DG; Jorns JM; Jewell R; Saber ME; Haque R; Katz SJ
    Breast Cancer Res Treat; 2017 Jan; 161(2):375-384. PubMed ID: 27900490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate.
    Sarode VR; Xiang QD; Christie A; Collins R; Rao R; Leitch AM; Euhus D; Haley B
    Arch Pathol Lab Med; 2015 Jul; 139(7):922-8. PubMed ID: 26125432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery.
    Ţenea-Cojan TŞ; Macovei A; Păun I; Costin AI; Georgescu CV; Georgescu CC; Vladu IM; Ene CG; Radu L
    Rom J Morphol Embryol; 2018; 59(3):763-772. PubMed ID: 30534815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and Characterization of Novel Diagnostic Mouse Monoclonal Antibodies Against Human Estrogen Receptor Alpha and Progesterone Receptor.
    Hassanzadeh Makoui M; Mobini M; Khoshnoodi J; Judaki MA; Bahadori T; Ahmadi Zare H; Golsaz-Shirazi F; Moradi Tabriz H; Madjd Z; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2999-3007. PubMed ID: 36172662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling Canadian Quality Control Test Program for Steroid Hormone Receptors in Breast Cancer: Diagnostic Accuracy Study.
    Pérez T; Makrestsov N; Garatt J; Torlakovic E; Gilks CB; Mallett S
    Appl Immunohistochem Mol Morphol; 2016; 24(10):679-687. PubMed ID: 26200834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.